Two recent systematic reviews of randomized clinical trials highlight a distinct divide in the evidence supporting medical marijuana: while inhaled cannabis increases the likelihood of meaningful relief for adults with chronic non-cancer pain, regulated medical cannabis shows no clear benefit for treating insomnia. The findings come from separate research teams evaluating data across 13 pain trials and nine sleep studies, offering patients and healthcare providers a clearer picture of what controlled evidence actually supports.

In an analysis presented October 29 at the 2026 World Congress on Pain, researchers from McMaster University, the University of British Columbia, Cornell University, and partner institutions examined 13 randomized clinical trials involving 395 adults. According to The Marijuana Herald, patients using smoked or vaporized cannabis were 60% more likely to achieve at least a 30% reduction in chronic non-cancer pain compared to those given a placebo.

Conversely, an October 2026 Cochrane systematic review led by investigators at the Universidad Hospital Italiano de Buenos Aires and the University of Manitoba analyzed nine clinical studies involving 537 adults aged 18 to 76 with insomnia. According to ScienceDaily, the review found little to no clinically meaningful improvement in sleep quality, total sleep hours, or daytime functioning when comparing regulated medical cannabis to a placebo.

Evidence for Inhaled Cannabis and Chronic Pain

The pain meta-analysis evaluated randomized trials recorded in medical databases and trial registries through October 2025. Across the 13 trials, participants who received inhaled cannabis experienced an average additional reduction of 0.74 points on a 10-point pain intensity scale compared to placebo recipients. The researchers noted that the data provided moderate- to high-certainty evidence that inhaled cannabis offers clinically important pain relief for roughly 1 in 5 patients dealing with chronic non-cancer pain.

However, the benefits observed in the pain trials were largely confined to pain intensity itself. When the investigators looked at secondary outcomes—including physical functioning, emotional functioning, daily activities, and sleep quality—they found little or no measurable improvement during the study windows.

Patients using inhaled cannabis also experienced higher rates of mild, temporary side effects. Coughing occurred 13 percentage points more frequently in the cannabis groups than in the placebo groups, while dizziness was reported approximately 10 percentage points more often. Furthermore, the researchers cautioned that 11 of the 13 trials followed participants for five days or less, with a median follow-up of about 1.6 days, underscoring the need for longer-term studies to see if pain relief endures over time.

Why Insomnia Trials Show Uncertain Results

While many consumers turn to cannabis hoping for a restful night, the Cochrane review indicates that personal anecdotes do not consistently align with clinical trial outcomes. In the nine studies evaluated, 72.66% of the 537 adult participants were women, and the longest trial lasted 12 weeks, according to inkorr.com. Eight of the trials compared regulated medical cannabis—typically formulated as measured tablets, sprays, or oils containing tetrahydrocannabinol (THC), cannabidiol (CBD), or both—against an inactive placebo, while one study compared cannabis directly with amitriptyline, an antidepressant sometimes prescribed for sleep issues.

While ScienceDaily summarizes the broad findings across the nine studies and 537 participants, a breakdown of the review by The Better Sleep Clinic reports finer subgroup numbers: seven trials involving 374 participants specifically evaluated sleep quality or satisfaction, and six trials with 194 participants assessed total sleep duration. In that six-trial subgroup, the estimated difference in sleep duration was about eight additional minutes, with plausible effects ranging from roughly 23 minutes less sleep to 38 minutes more sleep—a wide margin that illustrates statistical uncertainty rather than a reliable benefit.

"The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia," lead author Dr. Lucia Varela of the University of Manitoba noted in the ScienceDaily report. "This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effects."

Similar to the pain trials, participants taking medical cannabis for insomnia were more likely to report mild adverse effects, such as dry mouth, dizziness, and fatigue, though researchers noted this finding was drawn from a small subset of studies. While there was some indication that medical cannabis might influence overall quality of life, the pooled results ranged from a slight decline to a substantial improvement, making the outcome highly uncertain.

What This Means for Patients and Consumers

Together, the two reviews illustrate that medical cannabis cannot be treated as a single, uniform therapy across different health conditions. Reporting by The Washington Post points out that the insomnia review did not separate smoked cannabis from edibles, gummies, or other formats, and notes that when patients with chronic pain report sleeping better after using cannabis, that improvement may be an indirect result of pain relief rather than a direct treatment effect on insomnia itself.

For patients in the United States navigating state medical cannabis programs or retail dispensaries, clinical researchers emphasize that trial-tested, regulated formulations do not automatically mirror consumer market products. Dispensary offerings vary widely in THC and CBD ratios, dosages, and delivery methods. For individuals struggling with primary insomnia, sleep specialists continue to recommend cognitive behavioral therapy and established prescription medications as first-line treatments while calling for larger, longer, and more diverse clinical trials on cannabinoids.

Frequently Asked Questions

Does cannabis improve sleep if insomnia is caused by chronic pain?

It remains unclear. Most studies in the Cochrane insomnia review focused on primary insomnia—sleep difficulties not attributed to another medical condition. While coverage in The Washington Post notes that easing chronic pain could theoretically help pain patients rest more comfortably, the 13-trial review of inhaled cannabis for chronic pain found little or no direct improvement in sleep quality during its short study periods.

What side effects were reported in the clinical trials?

Across both reviews, adverse events were generally mild and temporary but occurred more frequently with cannabis than with a placebo. In the inhaled pain trials, coughing was 13 percentage points more common and dizziness was about 10 percentage points more common. In the insomnia trials testing oils, sprays, and tablets, participants more frequently noted dizziness, dry mouth, and fatigue.

How do trial-tested products compare to state dispensary products?

Clinical trials typically evaluate regulated medical products with carefully measured amounts of THC and CBD, or controlled inhaled protocols over very short periods (such as a median of 1.6 days in the pain review). Products sold in state cannabis markets vary significantly in potency, chemical composition, and delivery format, meaning clinical trial results cannot be broadly generalized to every retail gummy, oil, or flower product.

Sources